Skip to main content
Menu
Revvity logo
Contact us

Loading...

US
Search all

Loading...

Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

australia.webp Australia
austria.webp Austria
belgium.webp Belgium
brazil.webp Brazil *
canada.webp Canada
china.webp China *
denmark.webp Denmark
finland.webp Finland
france.webp France
germany.webp Germany
hong-kong.webp Hong Kong *
india.webp India *
ireland.webp Ireland
italy.webp Italy
japan.webp Japan *
luxembourg.webp Luxembourg
mexico.webp Mexico *
netherlands.webp Netherlands
norway.webp Norway
philippines.webp Philippines *
republic of korea.webp Republic of Korea *
singapore.webp Singapore *
spain.webp Spain
sweden.webp Sweden
switzerland.webp Switzerland
thailand.webp Thailand *
uk.webp United Kingdom
usa.webp United States
Login/Register here
Revvity web shop online account

Get exclusive pricing on all online purchases.

Login to your Revvity.com account for your account's pricing, easy re-ordering from favorites & order history, priority order processing, and dynamic order tracking.

Login Register
Revvity Omics portal accounts

Initiate a new order or access test status and results for clinical genomics or newborn screening services.

View login options
Breadcrumb
...
  • Home
  • A single-step process for engineering hypoimmunogenic pluripotent stem cells with the Pin-point™ platform
Interchanging-Cas-enzymes-deaminases-and-aptamer-guide-RNA1920x640.jpg
Scientific Poster

A single-step process for engineering hypoimmunogenic pluripotent stem cells with the Pin-point™ platform

Pluripotent stem cells (PSCs) hold great promise for the manufacturing of cell therapies. Off-the-shelf allogeneic products derived from PSCs engineered have the potential to dramatically broaden access to these therapies. However, their sensitivity to DNA damage presents challenges for efficiently performing the complex genome editing operations necessary to realise much of their potential.

Base editors represent a potential solution to these challenges due to their reduced genotoxicity compared to nuclease-based technologies.

In this poster, we demonstrate the power of the Pin-point™ base editing platform for the engineering of allogeneic PSCs.

The Pin-point platform technology is available for clinical study and commercialization under a commercial license from Revvity. Pin-point reagents are available for research use only.

Download Resource

A single-step process for engineering hypoimmunogenic pluripotent stem cells with the Pin-point™ platform

Download Scientific Poster
Revvity Logo

©2025 Revvity - All rights reserved

Revvity is a trademark of Revvity, Inc. All other trademarks are the property of their respective owners.